Corrigendum to, Is the patient’s baseline inhaled steroid dose a factor for choosing the budesonide/formoterol maintenance and reliever therapy regimen?, published in volume 5, issue 5 of Therapeutic Advances in Respiratory Disease [1].
The authors have noticed that in Figure 1 the bar representing rate of exacerbations per year/100 patients for high-dose ICS (HD) users with ICS at baseline ≥1600µg/day is incorrect. It should indicate: 185 exacerbations per year/100 patients.
Number of exacerbations per 100 patients during the year before study start according to baseline steroid dose.
A corrected version of Figure 1 from the above manuscript is presented below.
The authors apologise for this error and any confusion it may have caused.
References
1.
AubierMHaughneyJSelroosOvan SchayckOCPEkströmTOstinelliJ. (2011). Is the patient’s baseline inhaled steroid dose a factor for choosing the budesonide/formoterol maintenance and reliever therapy regimen?Ther Adv Respir Dis5: 289–298. [DOI: 10.1177/175346581140723610.1177/1753465811407236].
